World's Best Scientists 2026 revealed!
Anders Österborg

Anders Österborg

D-Index & Metrics

Medicine

D-Index
80
Citations
23991
World Ranking
17091
National Ranking
324

Overview

Anders Österborg is affiliated with the Karolinska Institute in Sweden and has an extensive body of research primarily within the field of medicine. Their work spans multiple subfields including genetics, immunology, pathology and forensic medicine, infectious diseases, and oncology. The main focus of Österborg's research involves chronic lymphocytic leukemia, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, as well as SARS-CoV-2 and COVID-19 clinical research.

Their frequent publication venues include Blood, Clinical Lymphoma Myeloma & Leukemia, Haematologica, EBioMedicine, and the Journal of Clinical Oncology.

Frequent coauthors collaborating with Österborg include Lotta Hansson, Martin Šimkovič, Tadeusz Robak, Marcus Buggert, and Constantine S. Tam.

Representative recent papers by Österborg cover significant topics in hematology and infectious diseases. These include:

  • "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia," 2022, New England Journal of Medicine
  • "Outcomes of COVID-19 in patients with CLL: a multicenter international experience," 2020, Blood
  • "Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial," 2022, The Lancet Oncology
  • "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial," 2021, EBioMedicine
  • "Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities," 2022, NEJM Evidence

The main topics addressed in Österborg's work are:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research

The subfields of study associated with their publications include:

  • Genetics
  • Immunology
  • Pathology and Forensic Medicine
  • Infectious Diseases
  • Oncology

Österborg's research contributes to an understanding of hematological malignancies and immunological conditions across clinical and translational domains, with a notable emphasis on therapeutic strategies and responses to infectious diseases in immunocompromised populations.

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

    Jeanette Lundin;Eva Kimby;Magnus Björkholm;Per-Anders Broliden

  • Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

    Francesco D'Amore;Thomas Relander;Grete F. Lauritzsen;Esa Jantunen

  • Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

    A. Österborg;M. J. S. Dyer;D. Bunjes;G. A. Pangalis

  • Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

    Jeanette Lundin;Hans Hagberg;Roland Repp;Eva Cavallin-Ståhl

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

    C. Bokemeyer;M.S. Aapro;A. Courdi;J. Foubert

  • A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

    Gunilla Enblad;Hans Hagberg;Martin Erlanson;Jeanette Lundin

  • Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

    Eva Hellström-Lindberg;Tomas Ahlgren;Yves Beguin;Magnus Carlsson

  • Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

    Susan O'Brien;Susan O'Brien;Jeffrey A Jones;Steven E Coutre;Anthony R Mato;Anthony R Mato

  • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

    J Lundin;Anders Osterborg;G Brittinger;Derek Crowther

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

    C. Bokemeyer;M.S. Aapro;A. Courdi;J. Foubert

  • Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

    Anders ÖSterborg;Athanasios S. Fassas;Achilles Anagnostopoulos;Martin J. S. Dyer

  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

    Anthony R. Mato;Lindsey E. Roeker;Nicole Lamanna;John N. Allan

  • Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

    A Osterborg;MA Boogaerts;R Cimino;U Essers

  • Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses

    Anders Österborg;Qing Yi;Lotta Henriksson;Jan Fagerberg

  • Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

    Geoff Hale;Peppy Rebello;Lee R. Brettman;Chris Fegan

  • Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†

    Aapro M;Beguin Y;Bokemeyer C;Dicato M

  • Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.

    Youn H. Kim;Madeleine Duvic;Erik Obitz;Robert Gniadecki

  • Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

    Amir H. DaneshManesh;Eva Mikaelsson;Mahmood Jeddi‐Tehrani;Ali Ahmad Bayat

Frequent Co-Authors

Håkan Mellstedt
Håkan Mellstedt Karolinska Institute
Mahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani Avicenna Research Institute
Magnus Björkholm
Magnus Björkholm Karolinska University Hospital
Peter Hillmen
Peter Hillmen St James's University Hospital
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Heinz Ludwig
Heinz Ludwig University of Vienna
Martin J. S. Dyer
Martin J. S. Dyer University of Leicester
Qing Yi
Qing Yi Houston Methodist
Bo Nilsson
Bo Nilsson Uppsala University
Yves Beguin
Yves Beguin University of Liège

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career in the USA, a wide range of online health degrees can expand your options. For those interested in healthcare leadership, explore the most affordable online mha programs to build management skills and improve your career prospects.

Advanced practice nurses may want to consider the most affordable online dnp programs, giving you flexibility to further your expertise while balancing work and family commitments.

Interested in the pharmaceutical field? Learn more about online pharmacy school cost to plan your financial investment and choose the best program for your goals.

Finally, for students who want to work at the intersection of health and technology, a health information management degree online can lead to dynamic careers in a rapidly growing sector. Each pathway has its own unique requirements, costs, and career outcomes, so explore your options to find the best fit for your future.

Best Scientists Citing Anders Österborg

Trending Scientists

Recently Published Articles